His particular interest is using his technical and scientific skills and knowledge to link research to the customer's needs.
In the field of laboratory diagnostics, he has been involved in the development and promotion of several ground-breaking products including the first commercial assays for neonatal TSH, anti-gliadin IgA and a range of inflammatory biomarkers.
In the drug discovery industry, Martin has worked widely with novel cell and tissue injury biomarkers and their application to toxicology and drug discovery.
Martin has participated in industry-wide consortia on the qualification on biomarkers for use in preclinical toxicology studies and phase I clinical trials
Martin has published several review articles on the application of biomarkers in drug discovery and he has lectured at many conferences, including twice being guest speaker at the FDA.
Currently he is working with a novel exciting biomarker of cell proliferation - The AroCell TK 210 ELISA kit that has great potential as a biomarker of cell proliferation in preclinical drug development and clinical trials.